NBIX · XBRL financial data

Neurocrine Biosciences financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NBIX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,046	1,134	1,489	1,887	2,355	2,861
Cost of goods and services sold	10	14	23	40	34	52
Selling, general and administrative	433	583	753	888	1,007	1,156
Total operating expenses	883	1,031	—	—	—	—
Operating income (loss)	163	103	249	251	571	619
Interest expense	33	26	7	5	—	—
Income tax expense (benefit)	(301)	12	59	82	145	227
Net income (loss)	407	90	155	250	341	479
Earnings per share, basic USD per share	4.38	0.95	1.61	2.56	3.40	4.81
Earnings per share, diluted USD per share	4.16	0.92	1.56	2.47	3.29	4.67
Weighted average shares, basic millions of shares	93	95	96	98	100	100
Weighted average shares, diluted millions of shares	98	98	99	101	104	103

Fiscal years (NBIX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	187	341	263	251	233	713
Marketable securities	614	371	726	781	843	767
Marketable securities, non-current	227	561	299	688	740	1,063
Accounts receivable	157	186	350	439	479	687
Inventory	28	31	35	38	57	69
Total current assets	1,016	973	1,454	1,607	1,725	2,523
Property and equipment, net	45	59	59	71	83	90
Right-of-use asset	83	97	87	277	509	455
Goodwill	—	0	5	6	6	6
Total assets	1,735	2,073	2,369	3,251	3,719	4,632
Total current liabilities	187	246	538	655	508	743
Lease liability, non-current	94	105	94	258	455	415
Total liabilities	609	699	661	1,019	1,129	1,378
Retained earnings (accumulated deficit)	(725)	(636)	(407)	(157)	29	448
Total stockholders' equity	1,126	1,374	1,708	2,232	2,590	3,253
Total liabilities and equity	1,735	2,073	2,369	3,251	3,719	4,632
Common shares outstanding (cover page) millions of shares	94	95	97	100	100	100

Fiscal years (NBIX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	407	90	155	250	341	479
Stock-based compensation	100	134	173	194	196	218
Net cash from operating activities	229	257	339	390	595	783
Purchases of property and equipment	11	23	17	28	38	34
Net cash from investing activities	4	(130)	(177)	(467)	(127)	(264)
Proceeds from issuing common stock	29	28	45	65	122	129
Share repurchases	—	—	0	0	300	168
Net cash from financing activities	(158)	27	(234)	65	(487)	(38)
Net change in cash	75	154	(73)	(12)	(18)	480

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
United Therapeutics	1,189	833	not reported	42.6M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.